Oral Oncology, Год журнала: 2021, Номер 121, С. 105332 - 105332
Опубликована: Июнь 14, 2021
Язык: Английский
Journal of Cancer Research and Clinical Oncology, Год журнала: 2023, Номер 149(14), С. 12597 - 12604
Опубликована: Июль 14, 2023
More than 99% of cervical cancers and up to 40% vulvar are human papillomavirus (HPV) related. HPV 16 18 the most relevant subtypes. Novel technologies allow detection minimal amounts circulating cell-free DNA (ccfHPV-DNA). The aim this study was evaluate ccfHPV-DNA assessed by droplet digital PCR (ddPCR) as a biomarker for molecular therapy monitoring in early, advanced, relapsed metastatic HPV-driven cancer.Inclusion criteria were histologically proven 16/18-driven cancer with first diagnosed disease, newly recurrence, or progression disease. Blood samples taken pre- post-therapeutically. Circulating quantified using ddPCR results correlated clinical data.The mean copy number 838.6 (± 3089.1) pretreatment 2.3 6.4) post-treatment (p < 0.05). increased higher FIGO stages 0.05), which commonly used staging/assessment. Furthermore, we compared distribution numbers between T-stage 1 versus 2/3. We could show level 2/3 0.05).Therapy determination small amount plasma reflects response appears feasible patients advanced cancer. This promising tool should be examined marker particular novel HPV-directed therapies.
Язык: Английский
Процитировано
16
Clinica Chimica Acta, Год журнала: 2023, Номер 542, С. 117269 - 117269
Опубликована: Фев. 24, 2023
Язык: Английский
Процитировано
11
Seminars in Radiation Oncology, Год журнала: 2023, Номер 33(3), С. 262 - 278
Опубликована: Июнь 16, 2023
Язык: Английский
Процитировано
11
Acta Oncologica, Год журнала: 2025, Номер 64, С. 1 - 12
Опубликована: Янв. 2, 2025
The similarities in biology, treatment regimens and outcome between the different human papillomavirus (HPV) associated squamous cell carcinomas (SCCs) allow for extrapolation of results generated from one SC tumor type to another. In HPV cancers, is integrated into genome can consequently be detected circulating fragments DNA. Thus, measurement plasma a surrogate DNA (ctDNA) holds promise as clinically relevant biomarker cancers. With present overview we aim status studies SCCs, clinical potential gaps knowledge, with overall facilitate next steps prospective trials.
Язык: Английский
Процитировано
0
Head & Neck, Год журнала: 2025, Номер unknown
Опубликована: Янв. 23, 2025
ABSTRACT Purpose Blood‐borne, cell‐free DNA has been proposed as a means of individualizing the management human papillomavirus (HPV)‐positive oropharyngeal carcinoma. Methods and Materials This study was designed based on Preferred Reporting Items for Systematic Review Meta‐Analysis Protocols (PRISMA‐P) statement. A comprehensive literature search peer‐reviewed publications from January 2013 to 2024 undertaken identify prospective studies pertaining use circulating HPV‐DNA Results total 11 were identified differed in their clinical design, methods, endpoints. Five included patients treated by chemoradiation; 3 surgery; 2 both; 1 not specified. The timing frequency draws highly variable. sample size ranged 16 262 (mean, 99 patients). Conclusions While interest is growing with integrating into practice, supporting evidence limited heterogeneity evidence.
Язык: Английский
Процитировано
0
HNO, Год журнала: 2025, Номер unknown
Опубликована: Янв. 30, 2025
Язык: Английский
Процитировано
0
Head & Neck, Год журнала: 2025, Номер unknown
Опубликована: Март 21, 2025
Head and neck squamous cell carcinoma remains challenging due to high recurrence rates poor survival outcomes. Developing precise technologies for disease burden assessment, treatment response, minimal residual (MRD) surveillance is crucial improving prognosis. This review explores the potential of liquid biopsy MRD detection. A novel TNM (LiTNM) staging system introduced, integrating biomarkers from saliva, surgical drain lymphatic fluid (SLF), peripheral blood. Proximal biopsies, particularly saliva SLF, offer advantages their proximity tumor microenvironment. Saliva demonstrates sensitivity in HPV-associated oropharyngeal cancers, while SLF holds identifying early postoperative recurrence. Despite these advancements, standardization validation remain challenges. Liquid approaches show promise monitoring, yet clinical implementation stages. The proposed LiTNM could complement by providing a molecular framework risk stratification. However, rigorous prospective studies are necessary validate its utility facilitate adoption.
Язык: Английский
Процитировано
0
Oral Oncology, Год журнала: 2025, Номер 164, С. 107262 - 107262
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
Clinical Otolaryngology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 22, 2025
ABSTRACT Objectives HPV‐positive oropharyngeal squamous cell carcinoma (OPSCC) and head neck of unknown primary (HNCUP) are increasing. Despite good prognosis, recurrence rates range from 10% to 25%. Surveillance with clinical controls imaging is not always reliable. Circulating tumour human papillomavirus DNA (ctHPV‐DNA) has emerged as a potential biomarker for treatment evaluation detection recurrence. We aimed investigate the correlation between ctHPV‐DNA in HPV+ OPSCC/HNCUP radiologic burden. Additionally, we sought assess whether could serve tool evaluation. Design A prospective observational cohort study. Setting This multicenter study involved three otolaryngology units located central Sweden. utilised HPV genotype‐specific assays droplet digital PCR (ddPCR) detect plasma at diagnosis follow‐up. levels were correlated radiological burden response using Kendall Rank coefficient Kruskal–Wallis test. Participants Patients undergoing definitive (chemo)radiotherapy enrolled CIRCOS Results Out 54 patients, 51 eligible analyses. At baseline, was detectable 88%. majority patients favourable according RECIST had corresponding undetectable The baseline total volume nodal ( rτ = 0.39, p < 0.01, respectively 0.26, 0.01). Conclusion shows strengthens role promising HPV‐related OPC/HNCUP. With further research on serial sampling, complement OPSCC/HNCUP. Trial Registration: NCT05904327 [ ClinicalTrials.gov ]
Язык: Английский
Процитировано
0
Oral Oncology, Год журнала: 2023, Номер 143, С. 106436 - 106436
Опубликована: Июнь 1, 2023
Язык: Английский
Процитировано
10